Acurx Phamaceuticals, Inc.’s (NASDAQ: ACXP) ($ACXP) interview with David Luci, President / CEO


David Luci, the President and CEO at Acurx Phamaceuticals, Inc. (NASDAQ: ACXP) ($ACXP), is back for another Nasdaq Marketplace studio interview with New to The Street’s TV Host Jane King. ACXP is a clinical biopharmaceutical business developing a new class of antibiotics for bacterial infections. These antibiotics are first-in-class Pol IIIC inhibitors that block the Pol IIIC enzyme responsible for the bacteria infections in Clostridioides difficile infections (C. diff) (CDI) and MRSA (methicillin-resistant Staphylococcus aureus). Many hospital and nursing home patients can get infected with C. diff and MRSA (methicillin-resistant Staphylococcus aureus) during their stays. David tells viewers that about 29,000 people die from C. diff yearly, with over 500,000 getting the infection. The Company’s novel Ibezapolstat drug has microbiome data showing results after 3-days of treatment based on current trials. The drug is in FDA Phase 2b trials and is under the FDA’s “Fast Track” designation for treating patients with C. diff. The second drug in ACXP’s pipeline is ACX-375C, a potential drug to overcome MRSA infections. Disease data shows that MRSA accounts for 52% of US hospital inpatient infections. Management expects to file an FDA IDA at the end of 2023 to proceed with ACX-375C clinical trials. David tells viewers that the Company’s short-term goals are to continue finding non-dilutive financial grants and work on territorial license agreements for each drug. Viewers can expect David for a follow-up interview about the Company and its pipeline of drugs. The on-screen QR code is available during the show; download or visit Acurx Pharmaceticals, Inc. –

To make sure you never miss a video from New to the Street, click here to subscribe:

Follow New to the Street on Twitter:

Follow New to the Street on Facebook:

Follow New to the Street on Instagram:

Follow New to the Street on Rumble:

About New to the Street:

Subscribe to our Mailing List: